The Revised International Prognostic Scoring System (IPSS-R) Predicts Posttransplantation Outcome Of Patients With Myelodysplastic Syndrome Receiving Allogeneic Stem Cell Transplantation: A Basis For Clinical Decision Making

• Published in: Blood 2013-11, Vol.122 (21), p.2765-2765
• Main Authors: Della Porta, Matteo G, Alessandrino, Emilio Paolo, Bacigalupo, Andrea, Allione, Bernardino, Malcovati, Luca, van Lint, Maria Teresa, Bernardi, Massimo, Onida, Francesco, Bosi, Alberto, Iori, Anna Paola, Cerretti, Raffaella, Marenco, Paola, Pioltelli, Pietro, Angelucci, Emanuele, Oneto, Rosi, Pascutto, Cristiana, Cazzola, Mario, Rambaldi, Alessandro
• Format: Article
• Language: English
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V122.21.2765.2765

The only curative treatment for patients with myelodysplastic syndrome (MDS) is allogeneic stem cell transplantation (allo-SCT). Decision to transplant is currently based on the International Prognostic Scoring System (IPSS), which has limitations. Recently, a revised IPSS (IPSS-R) has been developed (Blood. 2012;120:2454-2465). To identify predictive factors for transplantation outcome, we studied 519 patients with MDS or acute myeloid leukemia (AML) evolving from MDS who received allo-SCT and were reported to the GITMO registry between 2000 and 2010. Posttransplantation outcome according to cytogenetics. Cytogenetic abnormalities were classified according to MDS Cytogenetic Scoring System (MCSS) criteria. Four groups of patients with different overall survival (5-year OS ranging from 48% to 15%, P=.003) and probability of relapse (P=.001) after transplantation were identified. In a multivariate model, MCSS significantly affected OS (HR 1.29, P=.001) and probability of relapse (HR 1.40, P